empagliflozin/insulin

Indications

• investigational treatment of Alzheimer's disease

Dosage

• intranasal QID
  • dosage sketchy: 40 units regular insulin QID, 10 mg empaglifozin QD

Clinical trials

• beneficial effects on cognition & immune & inflammatory biomarkers in patients with mild cognitive impairment or early Alzheimer's disease in a phase 2 trial
  • biomarkers in included TREM2, SPP1, MMP9, PD-L1 & CX3CL1